When looking at isolate, it is important to verify the purity. While many are in the 99.9+% range with no identifiable amounts of THC, there are lower purity ones (such as 99.5% or lower) that may still have trace amounts that show up on the labs. This small amount is typically negligible, and is nowhere near the amount usually found in full spectrum products. But it’s still something to be aware of for those seeking the purest they can find.

There’s no definite amount that’s appropriate for everyone, but the ratio of CBD to THC will indicate how psychoactive the product is and if it’s legal in your state. The more CBD compared with THC, the less of a high, and vice versa. “Managing psychoactivity is key to successful cannabis therapy,” says Lee. “Amounts should be made clear on the label and lab-certified so people know what’s helping them and what’s not.”
Disclaimer: The information provided on this site is intended for your general knowledge only and is not a substitute for professional medical advice or treatment for specific medical conditions. You should not use this information to diagnose or treat a health problem or disease without consulting with a qualified healthcare provider. Please consult your healthcare provider with any questions or concerns you may have regarding your condition. Your use of this website indicates your agreement to this websites published terms of use and all site policies. Please see our Medical Disclaimer for more information.
'If you have a health condition, or are taking any prescribed or over-the-counter medicines, always check with your doctor or a pharmacist for possible drug supplement interactions before taking CBD,' says Dr Brewer. 'This is because CBD interacts with enzymes involved in metabolising some medicines and may result in increased drug levels that could cause side effects.
Zuardi, A. W., Crippa, J. A., Hallak, J. E., Bhattacharyya, S., Atakan, Z., Martin-Santos, R., … & Guimarães, F. S. (2012). A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation [Abstract]. Current Pharmaceutical Design, 18(32), 5,131–5,140. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/22716160
×